Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Cereberus who wrote (213)	4/12/1998 12:12:00 AM
From: Andrew Q. Viet	Read Replies (1) \| Respond to of 712

The market had embraced the possibility that Aggrastat might have been approved for both angioplasty and unstable angina. Now we have learned the fact that Aggrastat was only approved for angioplasty, so I believe this is good news for CORR and CORR stock price might go up on Monday. The more profound question is: of the three drugs, rheopro, aggrastat and integrilin, which one is the most efficacious and the cheapest to make? Those factors will more likely determine the long term price trend for CORR.